A Single-centre, Double-blind, Double-dummy, Randomised, Crossover Study to Investigate the Effect of Formoterol HFA-pMDI Versus Salmeterol HFA-pMDI on Small Airways Physiological Parameters in COPD Patients

Trial Profile

A Single-centre, Double-blind, Double-dummy, Randomised, Crossover Study to Investigate the Effect of Formoterol HFA-pMDI Versus Salmeterol HFA-pMDI on Small Airways Physiological Parameters in COPD Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Formoterol (Primary) ; Formoterol (Primary) ; Salmeterol; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms IMPERIAL
  • Sponsors Chiesi Farmaceutici SpA
  • Most Recent Events

    • 18 Oct 2012 Planned number of patients changed from 30 to 40 as reported by EudraCT.
    • 14 Feb 2012 Planned End Date changed from 1 Mar 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 03 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top